文献速递消化道肿瘤与早癌消化内镜

首轮粪便免疫化学试验浓度可预测第二轮筛查中的结直肠癌和进展期肿瘤

First-Round Fecal Immunochemical Test Concentration Predicts Colorectal Cancer and Advanced Neoplasia in Second-Round Screening.
PubMed 文献 · Am J Gastroenterol · 2025-08-25

基于瑞典结肠筛查随机对照试验FIT组数据,纳入首轮FIT阴性(<10 μg Hb/g)且第二轮FIT阳性(≥10 μg Hb/g)并接受结肠镜检查的1991人,分析首轮FIT浓度与第二轮结直肠肿瘤检出的关联。结果显示首轮FIT浓度升高与第二轮结直肠癌和进展期肿瘤风险增加相关,提示结合两轮FIT结果可提升筛查效果。

要点

  • 首轮FIT浓度升高与第二轮结直肠癌及进展期肿瘤风险增加相关
  • 首轮FIT 6.0-9.9 μg Hb/g者进展期肿瘤风险比为1.85
  • 联合首轮与第二轮FIT结果可能提升筛查效能

核心结论

  • 即使首轮FIT浓度在低水平范围内升高,也与未来结直肠癌和进展期肿瘤检出相关。
  • 结合首轮和第二轮FIT结果可能增强筛查效果。

研究设计与样本

  • 基于瑞典结肠筛查随机对照试验FIT组的横断面分析。
  • 纳入首轮2次FIT阴性(<10 μg Hb/g粪便)且第二轮(2年后)FIT阳性(≥10 μg Hb/g粪便)并接受结肠镜检查的1991人。
  • 采用二元回归模型评估结直肠肿瘤风险因素。

主要发现

  • 首轮和第二轮FIT浓度中位数分别为2.2和21.8 μg Hb/g粪便。
  • 与首轮FIT浓度0.0-1.9 μg Hb/g粪便者相比,2.0-5.9和6.0-9.9 μg Hb/g者的进展期肿瘤风险比分别为1.38(95%CI 1.07-1.80)和1.85(95%CI 1.38-2.48)。
  • 在第二轮FIT浓度固定时,进展期肿瘤绝对风险随首轮FIT浓度升高而增加。

临床怎么用

  • 在FIT筛查程序中,可考虑结合首轮FIT浓度评估个体结直肠肿瘤风险。
  • 对首轮FIT浓度较高但仍在阴性范围内者,可加强后续筛查监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Enhancing fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening requires identifying additional predictive factors for colorectal neoplasia beyond current-round FIT concentration. We investigated whether first-round FIT concentration could predict colorectal neoplasia detection in the second screening round, using data from the randomized controlled trial Screening of Swedish Colons. METHODS: We conducted a cross-sectional analysis of Screening of Swedish Colons FIT-arm participants with negative 2-stool FIT (<10 μg Hb/g feces) in the first screening round, followed by a positive FIT (≥10 μg Hb/g feces) in the second round 2 years later with workup colonoscopy. We used binary regression models to assess risk factors for colorectal neoplasia, including CRC and advanced colorectal neoplasia (ACN), at colonoscopy, according to participants' characteristics and first-round and second-round FIT concentrations. RESULTS: In total, 1,991 individuals were included, with median FIT concentrations of 2.2 and 21.8 μg Hb/g feces in the first and second rounds, respectively. Higher first-round FIT concentration was associated with increased risks of CRC and ACN in the second round. Compared with those with first-round FIT concentrations of 0.0-1.9 μg Hb/g feces, the risk ratios for ACN were 1.38 (95% confidence interval 1.07-1.80) for 2.0-5.9 and 1.85 (95% confidence interval 1.38-2.48) for 6.0-9.9 μg Hb/g feces. For fixed second-round FIT concentration, the absolute risk of ACN increased in accordance with higher first-round FIT concentration. DISCUSSION: Even an increase in low levels of FIT concentration is associated with future CRC and ACN detection. Combining first-round and second-round FIT results could enhance the efficacy of screening.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Sekiguchi M, Westerberg M, Löwbeer C, et al. First-Round Fecal Immunochemical Test Concentration Predicts Colorectal Cancer and Advanced Neoplasia in Second-Round Screening. Am J Gastroenterol. 2025. PMID: 40853361. doi:10.14309/ajg.0000000000003738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。